| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2005 | WO2003106450A8 Phenylaminopyrimidines and their use as rho-kinase inhibitors |
| 02/03/2005 | WO2003101461A8 Norethindrone sustained release formulations and methods associated therewith |
| 02/03/2005 | WO2003096988A3 Tr4/tr2 response elements |
| 02/03/2005 | WO2003094859A3 Epha2 monoclonal antibodies and methods of use thereof |
| 02/03/2005 | WO2003063779A3 Selective analgesic agents |
| 02/03/2005 | WO2003062390A3 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 02/03/2005 | WO2003039342A3 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 |
| 02/03/2005 | WO2003037248A3 Fibrin nanoparticles and uses thereof |
| 02/03/2005 | WO2002096360A3 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 02/03/2005 | US20050027129 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 02/03/2005 | US20050027125 Intensifiers of adenosine receptors for cardiac arrhythmia |
| 02/03/2005 | US20050027121 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases |
| 02/03/2005 | US20050027114 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 02/03/2005 | US20050027044 Process of making press molded materials using heat activated tertiary amine urethane catalysts |
| 02/03/2005 | US20050027019 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 02/03/2005 | US20050027018 Polymorphs of butylated hydroxy anisole |
| 02/03/2005 | US20050027017 Rhinologically active substances |
| 02/03/2005 | US20050027016 Polyamine compounds and compositions for use in conjection with cancer therapy |
| 02/03/2005 | US20050027015 Feed containing cysteamine or a salt thereof and a stabilizer such as cyclodextrin; increased milk production in cows |
| 02/03/2005 | US20050027014 And other diseases such as Down's syndrome related to A beta peptide, a component of amyloid plaques; inhibitors of the beta-secretase enzyme |
| 02/03/2005 | US20050027013 LTA4 hydrolase inhibitors |
| 02/03/2005 | US20050027012 In a core, with a film around the core; high dosages; short release time, sufficient mechanical stability, and good tabletting qualities |
| 02/03/2005 | US20050027011 Preparing a solution of paroxetine hydrochloride and a water-soluble polymer dissolved in a cosolvent of a volatile organic solvent and water, and drying to form amorphous paroxetine hydrochloride in a water soluble matrix; nonhygroscopic; oral dosage forms |
| 02/03/2005 | US20050027010 Control of protozoa and protozoan cysts that harbor legionella |
| 02/03/2005 | US20050027009 New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 02/03/2005 | US20050027008 Having phenyl or naphthyl moeity; Secondary carbocyclic amides such as 2-(4-(2-naphthyloxy)-benzamido)benzoic acid methyl ester; cytotoxic activity against human cancer cells |
| 02/03/2005 | US20050027007 Allylamides useful in the treatment of alzheimer's disease |
| 02/03/2005 | US20050027006 Methods and materials for treating conditions associated with metabolic disorders |
| 02/03/2005 | US20050027005 Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner |
| 02/03/2005 | US20050027004 Also Retinitis pigmentosa, senile dementia, diabetes-induced neuropathy, multiple sclerosis, cystic fibrosis, amyotrophic lateral sclerosis (ALS), cerebral palsy, Usher's syndrome, Huntington's disease and schizophrenia; oral administration such as in a food product; in microbial oil |
| 02/03/2005 | US20050027003 Using retinoids such as tazarotene at specific blood concentrations |
| 02/03/2005 | US20050027002 Heat activated tertiary amine urethane catalysts |
| 02/03/2005 | US20050027000 Use of apogossypol derivatives to treat cancer; drug screening for Bcl-2 protein inhibitors |
| 02/03/2005 | US20050026997 Baccatin III analog containing a small peptide moiety; can be conjugated to cell binding agents; improved potency |
| 02/03/2005 | US20050026996 A taxane such as paclitaxel or docetaxel joined by a hydrolyzable bond to one or more oligomers having a polyethylene glycol moiety; amphiphilic drug conjugate with improved water solubility without drastic increase in molecular weight |
| 02/03/2005 | US20050026995 anticarcinogenic agents comprising a mixture of taxol, solubilizers, stabilizers and anhydrous ethanol, having superior solubility, stability, bioavailability and side effect reduction |
| 02/03/2005 | US20050026993 Uses of ion channel modulating compounds |
| 02/03/2005 | US20050026992 Treatment and prevention of cardiovascular events |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026988 Cyclopenta'b! indole derivatives as spla inhibitors |
| 02/03/2005 | US20050026987 CBI analogues of the duocarmycins and CC-1065 |
| 02/03/2005 | US20050026986 Use of central cannabinoid receptor antagonists for the preparation of drugs |
| 02/03/2005 | US20050026985 Such as N-{5-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide; useful for the treatment of mammalian infertility |
| 02/03/2005 | US20050026983 Imidazole compounds and uses thereof |
| 02/03/2005 | US20050026982 Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026980 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases |
| 02/03/2005 | US20050026979 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| 02/03/2005 | US20050026977 Controlling dosage; sustained and significant weight loss in an overweight subject |
| 02/03/2005 | US20050026975 Such as ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate use in the treatment of disease mediated by monocyte chemoattractant protein-1 |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026972 Benzimidazol-or indol-aminoacetonitrile derivatives for parasite control |
| 02/03/2005 | US20050026969 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors |
| 02/03/2005 | US20050026968 Heterocyclic amides with anti-tuberculosis activity |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026963 Pyrazole substituted directly, or by a bridge, with a heteroaryl group containing N adjacent to the point of connection of the heteroaryl useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, bipolar disorder, circadian rhythm and sleep disorders |
| 02/03/2005 | US20050026961 Administering non-steroid antiinflammoatory agents selected from propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxyclic acid derivatives, oxicams together with domperidone or derivatives for treating nausea and acute migraine |
| 02/03/2005 | US20050026960 3-((mono- or di-fluoro-benzimidazol-2-yl))-5-(4-methyl-5-(ethylaminomethyl)pyrid-3-yl)indazole; inhibitors of cyclin dependent kinases(CDK) for use treating cancer and other proliferative disorders such as retinopathy, rheumatoid arthritis |
| 02/03/2005 | US20050026959 Ethanol solvate of (-)-cis-2-(2-chloropheny)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1benzopyran-4-one |
| 02/03/2005 | US20050026958 Methods of therapeutic treatment using amounts of retinoid components |
| 02/03/2005 | US20050026957 Methods of treating nodulocystic acne |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026953 Alkaloid that inhibits biosynthesis of mycotoxins and method for screening for mycotoxin inhibitors |
| 02/03/2005 | US20050026952 Nicotinamide derivatives useful as PDE4 inhibitors |
| 02/03/2005 | US20050026951 Administering of tazarotene and/or tazarotenic to treat acne, psoriasis, skin disorders, atherosclerosis, leukemia, lymphomas, cancer, respiratory system disorders; side effect reduction |
| 02/03/2005 | US20050026950 Methods of therapeutic treatment using retinoids to achieve consistent bioavailability |
| 02/03/2005 | US20050026949 Methods of therapeutic treatment using amounts of retinoids without regard to body weight |
| 02/03/2005 | US20050026948 Inflammatory and/or obstructive respiratory tract disorders |
| 02/03/2005 | US20050026946 GSK-3 inhibitors |
| 02/03/2005 | US20050026943 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 02/03/2005 | US20050026942 Chemokine receptor binding heterocyclic compounds |
| 02/03/2005 | US20050026941 preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase used for prophylaxis of erectile dysfunction and cardiovascular disorders |
| 02/03/2005 | US20050026940 Processes for the preparation of substituted bicyclic derivatives |
| 02/03/2005 | US20050026938 Purine inhibitors of protein kinases, G proteins and polymerases |
| 02/03/2005 | US20050026937 Corticotropin Releasing Factor antagonists; antidepressants, anxiolytic agents; irritable bowel syndrome |
| 02/03/2005 | US20050026936 1,4-Dideoxy-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-D-ribitol derivatives or salts; parasite purine nucleoside, -hydrolase, -phosphorylase and/or phosphoribosyl transferase inhibitors; antiprotozoa, anticarcinogenic, antiinflammatory, and immunosuppressant agents; autoimmune diseases |
| 02/03/2005 | US20050026935 Compounds |
| 02/03/2005 | US20050026934 Dissolved in water; recrystallized, dehydrated; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus, hepatitis virus |
| 02/03/2005 | US20050026933 Administering a 3-cyanoquinoline derivative andcapecitabine, paclitaxel, 5-fluorouracil or cisplatin; antitumor and anticarcinogenic agents |
| 02/03/2005 | US20050026932 Adenosine A2a receptor antagonists |
| 02/03/2005 | US20050026931 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 02/03/2005 | US20050026930 1,3,4-Thiadiazole-2-sulfonyl-N-piperazine; 1,3,4-oxadiazole-2-sulfonyl-N-piperazine; oxazole-2-sulfonyl-N-piperazine; or thiazole-2-sulfonyl-N-piperazine derivatives; cyclization, coupling, amidation; peptide synthesis; peptide nucleic acids |
| 02/03/2005 | US20050026927 Pyrazole derivatives as psychopharmaceuticals |
| 02/03/2005 | US20050026926 N, N'-disubstituted piperazine compounds and their use as analgesics |
| 02/03/2005 | US20050026924 Compositions containing alpha-2-adrenergic agonist components |
| 02/03/2005 | US20050026922 For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine |
| 02/03/2005 | US20050026919 Administering to subject a cyclooxygenase-2 selective inhibitor or an isomer, salt, ester, or prodrug thereof in combination with a cholinergic agent or an isomer, salt, ester, or prodrug thereof; combination therapy for treating a stroke |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026912 Applying positive pressure to an extremity of the patient at a magnitude and for a duration sufficient to combat syndrome; may also include administering a medicament selected from benzodiazepines, dopamine agonists, carbidopa-levodopa, anti-convulsants and opiods |
| 02/03/2005 | US20050026909 2-(1-piperazinyl) thieno[2,3-d]pyrimidine derivatives having 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity; nocturia or overactive bladder |
| 02/03/2005 | US20050026906 Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide; for control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain |
| 02/03/2005 | US20050026905 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026903 Pyrazole compound; gastrointestinal disorders; central nervous system disorders |
| 02/03/2005 | US20050026901 Antihistaminic spiro compounds |
| 02/03/2005 | US20050026900 Metabolite |
| 02/03/2005 | US20050026899 11-Piperazin-1-yldibenzo[b,f][1,4]thiazepine or its pharmaceutically acceptable salts; for treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, negative and positive psychotic symptoms commonly associated with schizophrenia, dementia, anxiety, depression |
| 02/03/2005 | US20050026898 Semi-solid systems containing azetidine derivatives |
| 02/03/2005 | US20050026897 Trinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment |
| 02/03/2005 | US20050026894 2-Desmethyl ansamycin compounds |